A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055 by Xiao-Hong Zhou, Susanne Prothon, Engin Liathdale, Nicola Ferrari, Kebria Hezaveh, Zhi Liu, Szilard Nemes, Joachim Almquist, Michael L. Williams, Olami Sobande, Christer Gottfridsson, Bernadette R. Gochuico, Adam Platt, Zach Brohawn, Maria G. Belvisi, Ronald Goldwater, Ellinor Hornberg, Caroline A. Owen

Get full text